Retatrutide: difference between revisions
Diff·revision 21 → 22·08:57, 6 Apr 2025
Difference between revision 21 and revision 22 of Retatrutide. 2 lines changed; the page grew by 170 bytes.
| Revision 21 — 01:28, 16 Mar 2025 SemaglutideSasha (talk) expand §Material sold as retatrutide 5,700 bytes ±0 | Revision 22 — 08:57, 6 Apr 2025 ApoB_Aurelio (talk) add see also to the amylin analogue 5,870 bytes +170 | ||
|---|---|---|---|
| 53 | Two findings are specific to the glucagon component. A dose-dependent increase in heart rate was reported, larger than the two-to-four beats per minute typical of GLP-1 monotherapy and peaking during escalation before partially receding. Transient rises in fasting glucose were observed at the lowest dose in participants with diabetes, consistent with glucagon agonism outrunning GLP-1 agonism when the total dose is low — the predicted failure mode of the design. | 53 | Two findings are specific to the glucagon component. A dose-dependent increase in heart rate was reported, larger than the two-to-four beats per minute typical of GLP-1 monotherapy and peaking during escalation before partially receding. Transient rises in fasting glucose were observed at the lowest dose in participants with diabetes, consistent with glucagon agonism outrunning GLP-1 agonism when the total dose is low — the predicted failure mode of the design. |
| 54 | 54 | ||
| + | 55 | Long-term safety cannot be assessed from a 48-week phase 2 trial. This article will require revision as phase 3 data are published; the {{tl-update}} tag reflects that. | |
| + | 56 | ||
| 55 | == References == | 57 | == References == |
| 56 | {{reflist}} | 58 | {{reflist}} |